So, what if only 10% of people with Alzheimer’s have genetics that predispose them to effective treatment with Anavex 2-73? If that were the case (I don’t see that it will be), the drug”
I believe the % is far greater than 10%. I cant imagine the trial will start in a month if the % was only 10%. My guess is the % is at least 25%.
Seeing the news about a trial starting is very welcome news. Finally!!
Market Data 
Markets 
AI
